Filipe F Stoyell-Conti1,2, Sarin Itty3,4, Christy Abraham3,4, Katya Rigatto5,6, Crystal A West7, Robert C Speth8,9. 1. College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL, USA. 2. Department of Surgery, University of Miami, Miami, FL, USA. 3. Halmos College of Natural Science & Oceanography, Nova Southeastern University, Fort Lauderdale, FL, USA. 4. Kiran P. Patel College of Osteopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL, USA. 5. Institute for Neuro-Immune Medicine, Nova Southeastern University, Fort Lauderdale, FL, USA. 6. Laboratório de Fisiologia Translacional, Universidade Federal de Ciências da Saúde de Porto, Alegre, RS, Brazil. 7. Department of Biology, Appalachian State University, North Carolina Research Campus, Kannapolis, NC, USA. 8. College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL, USA. rs1251@nova.edu. 9. Department of Pharmacology and Physiology, School of Medicine, Georgetown University, Washington, DC, USA. rs1251@nova.edu.
Abstract
PURPOSE: To study the receptor for Angiotensin (Ang) 1-7 using a radioligand (125I-Ang 1-7)-binding assay. For more than a decade, Mas has been viewed as the receptor for Ang 1-7; however, Ang 1-7 binding has not been pharmacologically characterized in tissue membrane preparations. METHODS: Radioligand-binding assays were carried out using tissue membrane preparations using radioiodinated Angiotensin 1-7 (125I-Ang 1-7) to characterize its binding site. Non-radioactive 127I-Ang 1-7 was used to test if the addition of an iodine to the tyrosine4 moiety of Ang 1-7 changes the ability of Ang 1-7 to competitively inhibit 125I-Ang 1-7 binding. RESULTS: 125I-Ang 1-7 binds saturably, with moderately high affinity (10-20 nM) to a binding site in rat liver membranes that is displaceable by 127I-Ang 1-7 at nanomolar concentrations (IC50 = 62 nM) while Ang 1-7 displaces at micromolar concentrations (IC50 = 80 µM) at ~22 °C. This binding was also displaceable by inhibitors of metalloproteases at room temperature. This suggests that 125I-Ang 1-7 binds to MMPs and/or ADAMs as well as other liver membrane elements at ~ 22 °C. However, when 125I-Ang 1-7-binding assays were run at 0-4 °C, the same MMP inhibitors did not effectively compete for 125I-Ang 1-7. CONCLUSIONS: The addition of an iodine molecule to the tyrosine in position 4 of Ang 1-7 drastically changes the binding characteristics of this peptide making it unsuitable for characterization of Ang 1-7 receptors.
PURPOSE: To study the receptor for Angiotensin (Ang) 1-7 using a radioligand (125I-Ang 1-7)-binding assay. For more than a decade, Mas has been viewed as the receptor for Ang 1-7; however, Ang 1-7 binding has not been pharmacologically characterized in tissue membrane preparations. METHODS: Radioligand-binding assays were carried out using tissue membrane preparations using radioiodinated Angiotensin 1-7 (125I-Ang 1-7) to characterize its binding site. Non-radioactive 127I-Ang 1-7 was used to test if the addition of an iodine to the tyrosine4 moiety of Ang 1-7 changes the ability of Ang 1-7 to competitively inhibit 125I-Ang 1-7 binding. RESULTS: 125I-Ang 1-7 binds saturably, with moderately high affinity (10-20 nM) to a binding site in rat liver membranes that is displaceable by 127I-Ang 1-7 at nanomolar concentrations (IC50 = 62 nM) while Ang 1-7 displaces at micromolar concentrations (IC50 = 80 µM) at ~22 °C. This binding was also displaceable by inhibitors of metalloproteases at room temperature. This suggests that 125I-Ang 1-7 binds to MMPs and/or ADAMs as well as other liver membrane elements at ~ 22 °C. However, when 125I-Ang 1-7-binding assays were run at 0-4 °C, the same MMP inhibitors did not effectively compete for 125I-Ang 1-7. CONCLUSIONS: The addition of an iodine molecule to the tyrosine in position 4 of Ang 1-7 drastically changes the binding characteristics of this peptide making it unsuitable for characterization of Ang 1-7 receptors.
Authors: Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas Journal: Pharmacol Rev Date: 2015-10 Impact factor: 25.468
Authors: Daniel R Rhodes; Bushra Ateeq; Qi Cao; Scott A Tomlins; Rohit Mehra; Bharathi Laxman; Shanker Kalyana-Sundaram; Robert J Lonigro; Beth E Helgeson; Mahaveer S Bhojani; Alnawaz Rehemtulla; Celina G Kleer; Daniel F Hayes; Peter C Lucas; Sooryanarayana Varambally; Arul M Chinnaiyan Journal: Proc Natl Acad Sci U S A Date: 2009-06-01 Impact factor: 11.205
Authors: Matthew A Sparks; Steven D Crowley; Susan B Gurley; Maria Mirotsou; Thomas M Coffman Journal: Compr Physiol Date: 2014-07 Impact factor: 9.090
Authors: Rhiannon Coulson; Seng H Liew; Angela A Connelly; Nicholas S Yee; Siddhartha Deb; Beena Kumar; Ana C Vargas; Sandra A O'Toole; Adam C Parslow; Ashleigh Poh; Tracy Putoczki; Riley J Morrow; Mariah Alorro; Kyren A Lazarus; Evie F W Yeap; Kelly L Walton; Craig A Harrison; Natalie J Hannan; Amee J George; Colin D Clyne; Matthias Ernst; Andrew M Allen; Ashwini L Chand Journal: Oncotarget Date: 2017-03-21
Authors: Yunfang Xiong; Ran Ke; Qingyu Zhang; Wenjun Lan; Wanjun Yuan; Karol Nga Ieng Chan; Tom Roussel; Yifan Jiang; Jing Wu; Shuai Liu; Alice Sze Tsai Wong; Joong Sup Shim; Xuanjun Zhang; Ruiyu Xie; Nelson Dusetti; Juan Iovanna; Nagy Habib; Ling Peng; Leo Tsz On Lee Journal: Adv Sci (Weinh) Date: 2022-06-16 Impact factor: 17.521